TPIDB > Outstanding PI
Outstanding PI
2025 Plastic Surgery
2025 Psychiatry
2025 Infectious Disease
2025 Nephrology
2025 Thoracic Surgery
2025 Thoracic Medicine
2025 Neurology
2025 Gastroenterological Surgery
2025 Digestive System
2025 Family Medicine
2025 Rheumatology
2025 Urology
2025 Hematology & Oncology
2025 Otolaryngology
2025 General Surgery
2025 Cardiovascular Surgery
2025 Cardiovascular Diseases
2025 Endocrinology
2025 Pediatrics
Highlights
Number of Clinical Trials 74
1. Global leading PI: Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2022, doi:10.1016/s0140-6736(22)00313-0.
2. Great contribution to Pediatric Infectious Diseases
3. Early phase small-molecule drug/vaccine development
ChiuCheng-Hsun
- Linkou Chang Gung Medical Foundation
- CHANGHUA CHRISTIAN HOSPITAL
-
Division of Pediatrics
未分科
Division of Infectious Disease
Highlights
Number of Clinical Trials 68
JongYuh-Jyh
- Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital
-
Division of Pediatrics
未分科
Highlights
Number of Clinical Trials 26
NIYEN-HSUAN
- National Taiwan University Hospital
-
Division of Pediatrics
Digestive System Department
Division of General Internal Medicine
未分科
Highlights
Number of Clinical Trials 67
1.The diet therapy of inflammatory bowel disease: a multi-omic analysis
− Inflammatory Bowel Disease (IBD)
− Crohn's Disease
− Nutrition therapy microbiota
− Crohn's disease exclusion diet
2. Study to Evaluate Efficacy and Safety of MS-20 on Patients with Ulcerative Colitis
− Ulcerative colitis
− MS-20
3. Minimize the Risk of Infection-Related Cancers by Implementation of Microbiota Reprogramming
− HBV
− HIV
− HPV
− nasopharngeal carcinoma
− microbiology
4. Development of novel anti-allergic probiotics by gut microbiota metagenomic analysis in infant cohorts
− Allergic diseases
− Gut microbiota
− metabolites
− Prebiotics
− Probiotics
5. A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and
Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
− Ulcerative colitis
− Pediatric
6. Explore the biomarkers determining the evolution of liver fibrosis and the outcome of pediatric chronic liver disease
− Microbiota
7. Gut microbiota play a critical role in determining the age-dependent outcome of hepatitis B virus infection
− Microbiota
8. The oncofetal RBMY protein and gut microbiota dysbiosis facilitate the development and metastasis of hepatocellular carcinoma
− Hepatocellular Carcinoma (HCC)
− Metastasis
− microbiota
− Epithelial–Mesenchymal Transition
9. Explore the clinical impacts of cell-free DNA as a noninvasive diagnosis of liver injury in pediatric liver transplant patients
− Liver transplant
10. Development of precision microbiome-based interventions in chronic hepatitis B
− Chronic hepatitis B
− Gut microbiota
ChenShih-Hsiang
- Linkou Chang Gung Medical Foundation
-
Division of Pediatrics
Division of Hematology & Oncology
Highlights
Number of Clinical Trials 13